Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease

Autores
Acosta, Patricio Leandro; Caballero, Mauricio Tomás; Polack, Fernando Pedro
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
In 1967, infants and toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus (RSV) experienced an enhanced form of RSV disease characterized by high fever, bronchopneumonia, and wheezing when they became infected with wild-type virus in the community. Hospitalizations were frequent, and two immunized toddlers died upon infection with wild-type RSV. The enhanced disease was initially characterized as a "peribronchiolar monocytic infiltration with some excess in eosinophils." Decades of research defined enhanced RSV disease (ERD) as the result of immunization with antigens not processed in the cytoplasm, resulting in a nonprotective antibody response and CD4(+) T helper priming in the absence of cytotoxic T lymphocytes. This response to vaccination led to a pathogenic Th2 memory response with eosinophil and immune complex deposition in the lungs after RSV infection. In recent years, the field of RSV experienced significant changes. Numerous vaccine candidates with novel designs and formulations are approaching clinical trials, defying our previous understanding of favorable parameters for ERD. This review provides a succinct analysis of these parameters and explores criteria for assessing the risk of ERD in new vaccine candidates.
Fil: Acosta, Patricio Leandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Infant; Argentina
Fil: Caballero, Mauricio Tomás. Fundación Infant; Argentina
Fil: Polack, Fernando Pedro. University Medical Center; Estados Unidos. Fundación Infant; Argentina
Materia
RESPIRATORY SYNCYTIAL VIRUS
VACCINE
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/108494
Acceder
id CONICETDig_d18d0973cbb76ccdf4de1d8b6f5f575a
oai_identifier_str oai:ri.conicet.gov.ar:11336/108494
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Brief History and Characterization of Enhanced Respiratory Syncytial Virus DiseaseAcosta, Patricio LeandroCaballero, Mauricio TomásPolack, Fernando PedroRESPIRATORY SYNCYTIAL VIRUSVACCINEhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3In 1967, infants and toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus (RSV) experienced an enhanced form of RSV disease characterized by high fever, bronchopneumonia, and wheezing when they became infected with wild-type virus in the community. Hospitalizations were frequent, and two immunized toddlers died upon infection with wild-type RSV. The enhanced disease was initially characterized as a "peribronchiolar monocytic infiltration with some excess in eosinophils." Decades of research defined enhanced RSV disease (ERD) as the result of immunization with antigens not processed in the cytoplasm, resulting in a nonprotective antibody response and CD4(+) T helper priming in the absence of cytotoxic T lymphocytes. This response to vaccination led to a pathogenic Th2 memory response with eosinophil and immune complex deposition in the lungs after RSV infection. In recent years, the field of RSV experienced significant changes. Numerous vaccine candidates with novel designs and formulations are approaching clinical trials, defying our previous understanding of favorable parameters for ERD. This review provides a succinct analysis of these parameters and explores criteria for assessing the risk of ERD in new vaccine candidates.Fil: Acosta, Patricio Leandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Infant; ArgentinaFil: Caballero, Mauricio Tomás. Fundación Infant; ArgentinaFil: Polack, Fernando Pedro. University Medical Center; Estados Unidos. Fundación Infant; ArgentinaAmerican Society for Microbiology2015-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/108494Acosta, Patricio Leandro; Caballero, Mauricio Tomás; Polack, Fernando Pedro; Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease; American Society for Microbiology; Clinical and Vaccine Immunology; 12-2015; 1-71556-6811CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1128/CVI.00609-15info:eu-repo/semantics/altIdentifier/url/https://cvi.asm.org/content/23/3/189info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:03:28Zoai:ri.conicet.gov.ar:11336/108494instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:03:28.309CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
title Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
spellingShingle Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
Acosta, Patricio Leandro
RESPIRATORY SYNCYTIAL VIRUS
VACCINE
title_short Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
title_full Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
title_fullStr Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
title_full_unstemmed Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
title_sort Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease
dc.creator.none.fl_str_mv Acosta, Patricio Leandro
Caballero, Mauricio Tomás
Polack, Fernando Pedro
author Acosta, Patricio Leandro
author_facet Acosta, Patricio Leandro
Caballero, Mauricio Tomás
Polack, Fernando Pedro
author_role author
author2 Caballero, Mauricio Tomás
Polack, Fernando Pedro
author2_role author
author
dc.subject.none.fl_str_mv RESPIRATORY SYNCYTIAL VIRUS
VACCINE
topic RESPIRATORY SYNCYTIAL VIRUS
VACCINE
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv In 1967, infants and toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus (RSV) experienced an enhanced form of RSV disease characterized by high fever, bronchopneumonia, and wheezing when they became infected with wild-type virus in the community. Hospitalizations were frequent, and two immunized toddlers died upon infection with wild-type RSV. The enhanced disease was initially characterized as a "peribronchiolar monocytic infiltration with some excess in eosinophils." Decades of research defined enhanced RSV disease (ERD) as the result of immunization with antigens not processed in the cytoplasm, resulting in a nonprotective antibody response and CD4(+) T helper priming in the absence of cytotoxic T lymphocytes. This response to vaccination led to a pathogenic Th2 memory response with eosinophil and immune complex deposition in the lungs after RSV infection. In recent years, the field of RSV experienced significant changes. Numerous vaccine candidates with novel designs and formulations are approaching clinical trials, defying our previous understanding of favorable parameters for ERD. This review provides a succinct analysis of these parameters and explores criteria for assessing the risk of ERD in new vaccine candidates.
Fil: Acosta, Patricio Leandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación Infant; Argentina
Fil: Caballero, Mauricio Tomás. Fundación Infant; Argentina
Fil: Polack, Fernando Pedro. University Medical Center; Estados Unidos. Fundación Infant; Argentina
description In 1967, infants and toddlers immunized with a formalin-inactivated vaccine against respiratory syncytial virus (RSV) experienced an enhanced form of RSV disease characterized by high fever, bronchopneumonia, and wheezing when they became infected with wild-type virus in the community. Hospitalizations were frequent, and two immunized toddlers died upon infection with wild-type RSV. The enhanced disease was initially characterized as a "peribronchiolar monocytic infiltration with some excess in eosinophils." Decades of research defined enhanced RSV disease (ERD) as the result of immunization with antigens not processed in the cytoplasm, resulting in a nonprotective antibody response and CD4(+) T helper priming in the absence of cytotoxic T lymphocytes. This response to vaccination led to a pathogenic Th2 memory response with eosinophil and immune complex deposition in the lungs after RSV infection. In recent years, the field of RSV experienced significant changes. Numerous vaccine candidates with novel designs and formulations are approaching clinical trials, defying our previous understanding of favorable parameters for ERD. This review provides a succinct analysis of these parameters and explores criteria for assessing the risk of ERD in new vaccine candidates.
publishDate 2015
dc.date.none.fl_str_mv 2015-12
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/108494
Acosta, Patricio Leandro; Caballero, Mauricio Tomás; Polack, Fernando Pedro; Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease; American Society for Microbiology; Clinical and Vaccine Immunology; 12-2015; 1-7
1556-6811
CONICET Digital
CONICET
url http://hdl.handle.net/11336/108494
identifier_str_mv Acosta, Patricio Leandro; Caballero, Mauricio Tomás; Polack, Fernando Pedro; Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease; American Society for Microbiology; Clinical and Vaccine Immunology; 12-2015; 1-7
1556-6811
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.1128/CVI.00609-15
info:eu-repo/semantics/altIdentifier/url/https://cvi.asm.org/content/23/3/189
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1844613851411120128
score 13.070432

Publicaciones similares